BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6264-6276

  Segura, Miguel F ^a,b,e   Fontanals Cirera, Bárbara ^a,b   Gaziel Sovran, Avital ^a,b   Guijarro, María V ^a,b   Hanniford, Doug ^a,b   Zhang, Guangtao ^c   González Gomez, Pilar ^d   Morante, Marta ^a,b   Jubierre, Luz ^e   Zhang, Weijia ^c   Darvishian, Farbod ^a,b   Ohlmeyer, Michael ^c   Osman, Iman ^a,b   Zhou, Ming Ming ^c   Hernando, Eva ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BROMODOMAIN 2 PROTEIN; BROMODOMAIN 4 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MS 417; MS 436; REGULATOR PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOACCUMULATION; BRAF GENE; BRD2 GENE; BRD4 GENE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; EPIGENETICS; ERK1 GENE; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; METASTATIC MELANOMA; MOUSE; NEVUS; NEWBORN; NONHUMAN; ONCOGENE C MYC; ONCOGENE N RAS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION; SKP2 GENE; TRANSCRIPTION REGULATION; TUMOR GROWTH; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; EPIGENOMICS; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RANDOM ALLOCATION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84886045045     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0122-T     Document Type: Article

References (54)

1. Tsao H, Chin L, Garraway L.A., Fisher DE Melanoma: from mutations to medicine. Genes Dev 2012; 26:1131-55.
2. Krauthammer M, Kong Y, Ha B.H., Evans P., Bacchiocchi A, McCusker JP, et al Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012; 44:1006-14.
3. Hodis E, Watson IR, Kryukov G.V., Arold ST, Imielinski M, Theurillat JP, et al A landscape of driver mutations in melanoma. Cell 2012; 150: 251-63.
4. Kapoor A, Goldberg MS, Cumberland L.K., Ratnakumar K., Segura MF, Emanuel PO, et al The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 2010; 468: 1105-9.
5. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S., Orlando DA, Battisti V, et al The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011; 471:513-7.
6. Lian CG, Xu Y, Ceol C., Wu F, Larson A, Dresser K., et al Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012; 150:1135-46.
7. Dhalluin C, Carlson JE, Zeng L, He C., Aggarwal AK, Zhou MM Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999; 399:491-6.
8. Sanchez R, Zhou MM The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Dev 2009; 12: 659-65.
9. Tamkun JW, Deuring R, Scott M.P., Kissinger M., Pattatucci AM, Kaufman TC, et al brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell 1992; 68:561-72.
10. Ogryzko VV, Schiltz RL, Russanova V, Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87:953-9.
11. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996; 384:641-3.
12. Haynes SR, Dollard C, Winston F., Beck S, Trowsdale J, Dawid IB The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins. Nucleic Acids Res 1992; 20:2603.
13. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q., Ma L, Agno JE, et al Small-molecule inhibition of BRDT for male contraception. Cell 2012; 150:673-84.
14. Belkina AC, Denis GV BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 2012; 12:465-77.
15. Greenwald RJ, Tumang JR, Sinha A, Currier N., Cardiff RD, Rothstein TL, et al E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 2004; 103:1475-84.
16. Denis GV, Green MR A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator. Genes Dev 1996; 10:261-71.
17. French CA, Miyoshi I, Kubonishi I., Grier HE, Perez-Atayde AR, Fletcher JA BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 2003; 63:304-7.
18. Reynoird N, Schwartz BE, Delvecchio M, Sadoul K., Meyers D, Mukherjee C, et al Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J 2010; 29:2943-52.
19. Crawford NP, Alsarraj J, Lukes L., Walker RC, Officewala JS, Yang HH, et al Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci U S A 2008; 105:6380-5.
20. Yang Z, Yik JH, Chen R, He N., Jang MK, Ozato K, et al Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 2005; 19:535-45.
21. Jang MK, Mochizuki K, Zhou M., Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of PTEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 2005; 19:523-34.
22. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G., Bantscheff M, Chan WI, et al Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478: 529-33.
23. Delmore JE, Issa GC, Lemieux M.E., Rahl PB, Shi J, Jacobs HM, et al BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146:904-17.
24. Lockwood WW, Zejnullahu K, Bradner J.E., Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A 2012; 109: 19408-13.
25. Rose AE, Poliseno L, Wang J., Clark M, Pearlman A, Wang G., et al Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res 2011; 71: 2561-71.
26. Talantov D, Mazumder A, Yu J.X., Briggs T., Jiang Y, Backus J, et al Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11:7234-42.
27. Segura MF, Hanniford D, Menendez S., Reavie L, Zou X, Alvarez-Diaz S, et al Aberrant miR-182 expression promotes melanomametastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 2009; 106:1814-9.
28. Livak KJ, Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25:402-8.
29. Filippakopoulos P, Qi J, Picaud S., Shen Y, Smith WB, Fedorov O, et al Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-73.
30. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S., Dewell S, Chung CW, et al Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468:1119-23.
31. Zhang G, Liu R, Zhong Y., Plotnikov AN, Zhang W, Zeng L, et al Down-regulation of NF-kappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem 2012; 287: 28840-51.
32. Riker AI, Enkemann SA, Fodstad O, Liu S., Ren S, Morris C, et al The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008; 1:13.
33. Chin L, Garraway LA, Fisher DE Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006; 20:2149-82.
34. Wajapeyee N, Serra RW, Zhu X, Mahalingam M., Green MR Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132:363-74.
35. Lin H, Wong RP, Martinka M, Li G. Loss of SNF5 expression correlates with poor patient survival in melanoma. Clin Cancer Res 2009; 15: 6404-11.
36. Yoo CB, Jones PA Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5:37-50.
37. Munster PN, Marchion D, Thomas S., Egorin M, Minton S, Springett G., et al Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009; 101:1044-50.
38. Dickson MA, Rathkopf DE, Carvajal R.D., Grant S., Roberts JD, Reid JM, et al A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Invest New Drugs 2011; 29: 1004-12.
39. Hauschild A, Trefzer U, Garbe C., Kaehler KC, Ugurel S, Kiecker F, et al Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 2008; 18: 274-8.
40. Hodi FS, O'Day SJ, McDermott DF, Weber R.W., Sosman JA, Haanen JB, et al Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23.
41. Flaherty KT, Puzanov I, Kim K.B., Ribas A., McArthur GA, Sosman JA, et al Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19.
42. Johannessen CM, Boehm JS, Kim S.Y., Thomas SR, Wardwell L, Johnson LA, et al COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-72.
43. Nazarian R, Shi H, Wang Q., Kong X, Koya RC, Lee H, et al Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973-7.
44. Poulikakos PI, Persaud Y, Janakiraman M., Kong X, Ng C, Moriceau G., et al RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387-90.
45. Mertz JA, Conery AR, Bryant B.M., Sandy P., Balasubramanian S, Mele DA, et al Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011; 108:16669-74.
46. Zuber J, Shi J, Wang E., Rappaport AR, Herrmann H, Sison EA, et al RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478:524-8.
47. Dawson MA, Kouzarides T, Huntly BJ Targeting epigenetic readers in cancer. N Engl J Med 2012; 367:647-57.
48. Borah JC, Mujtaba S, Karakikes I., Zeng L, Muller M, Patel J., et al A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol 2011; 18:531-41.
49. Mujtaba S, He Y, Zeng L., Yan S, Plotnikova O, Sachchidanand, et al. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 2004; 13:251-63.
50. Huang B, Yang XD, Zhou M.M., Ozato K., Chen LF Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol 2009; 29:1375-87.
51. Hou T, Ray S, Lee C., Brasier AR The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. J Biol Chem 2008; 283:30725-34.
52. Chiang CM. Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4. F1000 Biol Rep 2009; 1:98.
53. Young RA. Control of the embryonic stem cell state. Cell 2011; 144: 940-54.
54. White RM, Cech J, Ratanasirintrawoot S., Lin CY, Rahl PB, Burke CJ, et al DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 2011; 471:518-22.